{
  "description": "Comprehensive gold standard dataset for variant actionability assessment - includes SNVs, indels, fusions, and CNVs across multiple tumor types",
  "version": "2.0",
  "entries": [
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved BRAF inhibitors (vemurafenib, dabrafenib, encorafenib)",
      "references": ["Chapman PB et al. N Engl J Med 2011"]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved combination therapy with encorafenib + cetuximab",
      "references": ["Kopetz S et al. N Engl J Med 2019"]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Lung Adenocarcinoma",
      "expected_tier": "Tier II",
      "notes": "BRAF inhibitors show activity but not first-line therapy",
      "references": ["Planchard D et al. Lancet Oncol 2016"]
    },
    {
      "gene": "EGFR",
      "variant": "L858R",
      "tumor_type": "Lung Adenocarcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved EGFR TKIs (erlotinib, gefitinib, afatinib, osimertinib)",
      "references": ["Rosell R et al. Lancet Oncol 2012"]
    },
    {
      "gene": "EGFR",
      "variant": "exon 19 deletion",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved EGFR TKIs with strong response rates",
      "references": ["Mok TS et al. N Engl J Med 2009"]
    },
    {
      "gene": "EGFR",
      "variant": "T790M",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "Resistance to first/second-gen TKIs, sensitive to osimertinib",
      "references": ["Mok TS et al. N Engl J Med 2017"]
    },
    {
      "gene": "KRAS",
      "variant": "G12C",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved KRAS G12C inhibitors (sotorasib, adagrasib)",
      "references": ["Skoulidis F et al. N Engl J Med 2021"]
    },
    {
      "gene": "KRAS",
      "variant": "G12D",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier I",
      "notes": "Predicts resistance to anti-EGFR therapy (cetuximab, panitumumab)",
      "references": ["Lievre A et al. Cancer Res 2006"]
    },
    {
      "gene": "KRAS",
      "variant": "G12V",
      "tumor_type": "Pancreatic Cancer",
      "expected_tier": "Tier III",
      "notes": "Common driver mutation but no approved targeted therapy for pancreatic",
      "references": ["Waters AM et al. Cold Spring Harb Perspect Med 2018"]
    },
    {
      "gene": "ERBB2",
      "variant": "amplification",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved HER2-targeted therapies (trastuzumab, pertuzumab, T-DM1, T-DXd)",
      "references": ["Slamon DJ et al. N Engl J Med 2001"]
    },
    {
      "gene": "ERBB2",
      "variant": "amplification",
      "tumor_type": "Gastric Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved trastuzumab for HER2+ gastric cancer",
      "references": ["Bang YJ et al. Lancet 2010"]
    },
    {
      "gene": "ERBB2",
      "variant": "amplification",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier II",
      "notes": "Trastuzumab shows activity in trials but not FDA-approved",
      "references": ["Sartore-Bianchi A et al. Cancer Discov 2018"]
    },
    {
      "gene": "KIT",
      "variant": "D816V",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier I",
      "notes": "Resistance to imatinib, FDA-approved avapritinib for advanced GIST",
      "references": ["Heinrich MC et al. J Clin Oncol 2020"]
    },
    {
      "gene": "KIT",
      "variant": "exon 11 mutation",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier I",
      "notes": "FDA-approved imatinib for KIT-mutant GIST",
      "references": ["Demetri GD et al. N Engl J Med 2002"]
    },
    {
      "gene": "ALK",
      "variant": "fusion",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved ALK inhibitors (crizotinib, alectinib, ceritinib, brigatinib)",
      "references": ["Solomon BJ et al. N Engl J Med 2014"]
    },
    {
      "gene": "ALK",
      "variant": "fusion",
      "tumor_type": "Anaplastic Large Cell Lymphoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved crizotinib for ALK+ ALCL",
      "references": ["Gambacorti-Passerini C et al. Blood 2011"]
    },
    {
      "gene": "ROS1",
      "variant": "fusion",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved ROS1 inhibitors (crizotinib, entrectinib)",
      "references": ["Shaw AT et al. N Engl J Med 2014"]
    },
    {
      "gene": "RET",
      "variant": "fusion",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved selpercatinib and pralsetinib",
      "references": ["Drilon A et al. N Engl J Med 2020"]
    },
    {
      "gene": "RET",
      "variant": "fusion",
      "tumor_type": "Thyroid Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved selpercatinib for RET fusion-positive thyroid",
      "references": ["Wirth LJ et al. N Engl J Med 2020"]
    },
    {
      "gene": "NTRK1",
      "variant": "fusion",
      "tumor_type": "Solid Tumors",
      "expected_tier": "Tier I",
      "notes": "Tumor-agnostic FDA approval for larotrectinib and entrectinib",
      "references": ["Drilon A et al. N Engl J Med 2018"]
    },
    {
      "gene": "NTRK3",
      "variant": "fusion",
      "tumor_type": "Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "Tumor-agnostic FDA approval for NTRK fusions",
      "references": ["Doebele RC et al. Lancet Oncol 2020"]
    },
    {
      "gene": "FGFR2",
      "variant": "fusion",
      "tumor_type": "Cholangiocarcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved pemigatinib and infigratinib",
      "references": ["Abou-Alfa GK et al. Lancet Oncol 2020"]
    },
    {
      "gene": "FGFR3",
      "variant": "fusion",
      "tumor_type": "Urothelial Carcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved erdafitinib for FGFR-altered urothelial cancer",
      "references": ["Loriot Y et al. Lancet Oncol 2019"]
    },
    {
      "gene": "MET",
      "variant": "exon 14 skipping",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved capmatinib and tepotinib",
      "references": ["Wolf J et al. N Engl J Med 2020"]
    },
    {
      "gene": "MET",
      "variant": "amplification",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier II",
      "notes": "Emerging target, clinical trials ongoing",
      "references": ["Camidge DR et al. Lancet Oncol 2021"]
    },
    {
      "gene": "PIK3CA",
      "variant": "H1047R",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved alpelisib for PIK3CA-mutant HR+/HER2- breast cancer",
      "references": ["Andre F et al. N Engl J Med 2019"]
    },
    {
      "gene": "PIK3CA",
      "variant": "E545K",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved alpelisib for PIK3CA-mutant HR+/HER2- breast cancer",
      "references": ["Andre F et al. N Engl J Med 2019"]
    },
    {
      "gene": "BRCA1",
      "variant": "185delAG",
      "tumor_type": "Ovarian Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved PARP inhibitors (olaparib, rucaparib, niraparib)",
      "references": ["Moore K et al. N Engl J Med 2018"]
    },
    {
      "gene": "BRCA2",
      "variant": "6174delT",
      "tumor_type": "Prostate Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved PARP inhibitors and platinum chemotherapy",
      "references": ["de Bono J et al. N Engl J Med 2020"]
    },
    {
      "gene": "BRCA1",
      "variant": "truncating mutation",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved PARP inhibitors for germline BRCA-mutant breast",
      "references": ["Robson M et al. N Engl J Med 2017"]
    },
    {
      "gene": "IDH1",
      "variant": "R132H",
      "tumor_type": "Acute Myeloid Leukemia",
      "expected_tier": "Tier I",
      "notes": "FDA-approved ivosidenib for IDH1-mutant AML",
      "references": ["DiNardo CD et al. N Engl J Med 2018"]
    },
    {
      "gene": "IDH2",
      "variant": "R140Q",
      "tumor_type": "Acute Myeloid Leukemia",
      "expected_tier": "Tier I",
      "notes": "FDA-approved enasidenib for IDH2-mutant AML",
      "references": ["Stein EM et al. Blood 2017"]
    },
    {
      "gene": "IDH1",
      "variant": "R132H",
      "tumor_type": "Glioma",
      "expected_tier": "Tier II",
      "notes": "Vorasidenib shows activity in phase 3 trial but not yet FDA-approved",
      "references": ["Mellinghoff IK et al. N Engl J Med 2023"]
    },
    {
      "gene": "NRAS",
      "variant": "Q61K",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "No approved targeted therapies; MEK inhibitors show some activity",
      "references": ["Ascierto PA et al. Lancet Oncol 2013"]
    },
    {
      "gene": "NRAS",
      "variant": "Q61R",
      "tumor_type": "Thyroid Cancer",
      "expected_tier": "Tier III",
      "notes": "Driver mutation but no specific approved therapy",
      "references": ["Agrawal N et al. Cell 2014"]
    },
    {
      "gene": "TP53",
      "variant": "R175H",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier III",
      "notes": "Prognostic marker but no approved targeted therapy",
      "references": ["Olivier M et al. Cold Spring Harb Perspect Biol 2010"]
    },
    {
      "gene": "TP53",
      "variant": "R248W",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier III",
      "notes": "Common hotspot mutation but no actionable therapy",
      "references": ["Muller PA et al. Nat Rev Cancer 2013"]
    },
    {
      "gene": "APC",
      "variant": "truncating mutation",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier IV",
      "notes": "Driver mutation but no direct therapeutic implications",
      "references": ["Cancer Genome Atlas Network. Nature 2012"]
    },
    {
      "gene": "VHL",
      "variant": "loss of function",
      "tumor_type": "Renal Cell Carcinoma",
      "expected_tier": "Tier II",
      "notes": "Predicts response to angiogenesis inhibitors",
      "references": ["Sato Y et al. Cancer Res 2013"]
    },
    {
      "gene": "CDKN2A",
      "variant": "deletion",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "Prognostic significance but no targeted therapy",
      "references": ["Shain AH et al. N Engl J Med 2015"]
    },
    {
      "gene": "STK11",
      "variant": "inactivating mutation",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier III",
      "notes": "Associated with immunotherapy resistance but no approved therapy",
      "references": ["Skoulidis F et al. Cancer Discov 2018"]
    },
    {
      "gene": "PTEN",
      "variant": "loss of function",
      "tumor_type": "Endometrial Cancer",
      "expected_tier": "Tier III",
      "notes": "Common alteration but limited therapeutic options",
      "references": ["Cancer Genome Atlas Research Network. Nature 2013"]
    },
    {
      "gene": "NF1",
      "variant": "inactivating mutation",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "May predict MEK inhibitor response but not established",
      "references": ["Nissan MH et al. Cancer Discov 2014"]
    },
    {
      "gene": "MSI",
      "variant": "high",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier I",
      "notes": "Tumor-agnostic FDA approval for pembrolizumab/nivolumab",
      "references": ["Le DT et al. N Engl J Med 2015"]
    },
    {
      "gene": "TMB",
      "variant": "high",
      "tumor_type": "Solid Tumors",
      "expected_tier": "Tier II",
      "notes": "Associated with immunotherapy response but not absolute predictor",
      "references": ["Yarchoan M et al. N Engl J Med 2017"]
    }
  ]
}
